Paragraph 3: Conditions specific to the modality: "external radiotherapy, brachytherapy".

The weekly follow-up and the arrangements for coordinating the follow-up of the patient after treatment provided for in 3° and the fifth paragraph of article R. 6123-93 are recorded in the patient’s medical record.

The holder has an organisation enabling the radiotherapy team to: 1° Organise continuity of care on site for the patients it treats. This organisation may be pooled by agreement with another holder or authorised radiotherapy centre by setting up a joint team as referred to in II of Article D. 6124-133. 2° To guarantee continuity of radiotherapy treatment for the patients it treats, in the event of unavailability of radiotherapy…

An operating charter specific to the radiotherapy unit is drawn up by the authorisation holder and specifies in particular: 1° The organisation of the structure, with regard to the procedures for implementing the continuity of radiotherapy treatment provided for in 2 of Article D. 6124-133-11; 2° The radiotherapy equipment and techniques used by the radiotherapy structure. This charter is revised as soon as there are changes in the equipment and…

The licence holder must ensure that the particle accelerators used are connected to a system for systematically collecting and archiving dosimetric data.

The authorisation holder has an organisation that enables it to secure the information systems used to carry out radiotherapy treatment and to preserve all the data collected on the site.

The authorisation holder ensures that data from professional practices is collected and analysed with a view to improving practices and managing radiotherapy risks.

The authorisation holder is subject to the obligation of quality assurance defined in I of Article L. 1333-19.

The holder of the authorisation has the following facilities on the site: 1° At least one hospitalisation sector; 2° At least one technical platform for administering intravenous treatments; 3° Medical and paramedical consultation rooms; 4° An in-house pharmacy authorised to prepare anti-cancer drugs within a centralised cytotoxic preparation unit that complies with the recommendations for good practice issued by the Agence Nationale de Sécurité du Médicament et des Produits de…